BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 29548748)

  • 21. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo.
    Liu P; Mao H; Hou P
    Int J Gynecol Cancer; 2006; 16(2):538-48. PubMed ID: 16681723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
    Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
    Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notch1 expression correlates with tumor differentiation status in ovarian carcinoma.
    Wang M; Wang J; Wang L; Wu L; Xin X
    Med Oncol; 2010 Dec; 27(4):1329-35. PubMed ID: 20012562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
    Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P
    J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
    Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
    Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of long non-coding RNA TP73-AS1 inhibits cell proliferation and induces apoptosis in esophageal squamous cell carcinoma.
    Zang W; Wang T; Wang Y; Chen X; Du Y; Sun Q; Li M; Dong Z; Zhao G
    Oncotarget; 2016 Apr; 7(15):19960-74. PubMed ID: 26799587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calpain system protein expression and activity in ovarian cancer.
    Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer.
    Zhang YF; Li CS; Zhou Y; Lu XH
    Life Sci; 2020 Mar; 244():117280. PubMed ID: 31926239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of salusin-β is associated with poor prognosis in ovarian cancer.
    Zhang Q; Chen WM; Zhang XX; Zhang HX; Wang HC; Zheng FY; Zhu FF
    Oncol Rep; 2017 Mar; 37(3):1826-1832. PubMed ID: 28184918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA MALAT1 potentiates autophagy‑associated cisplatin resistance by regulating the microRNA‑30b/autophagy‑related gene 5 axis in gastric cancer.
    Xi Z; Si J; Nan J
    Int J Oncol; 2019 Jan; 54(1):239-248. PubMed ID: 30365113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of ARF1 is associated with cell proliferation and migration through PI3K signal pathway in ovarian cancer.
    Gu G; Chen Y; Duan C; Zhou L; Chen C; Chen J; Cheng J; Shi N; Jin Y; Xi Q; Zhong J
    Oncol Rep; 2017 Mar; 37(3):1511-1520. PubMed ID: 28098897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
    Yan P; Su Z; Zhang Z; Gao T
    Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S; Choi EJ; Jin C; Kim DH
    Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Long Non-Coding RNA MALAT1 Enhances Ovarian Cancer Cell Stemness by Inhibiting YAP Translocation from Nucleus to Cytoplasm.
    Wu X; Wang Y; Zhong W; Cheng H; Tian Z
    Med Sci Monit; 2020 May; 26():e922012. PubMed ID: 32433460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo.
    Zhang X; Wang X; Song X; Liu C; Shi Y; Wang Y; Afonja O; Ma C; Chen YH; Zhang L
    Cancer Sci; 2010 Oct; 101(10):2163-70. PubMed ID: 20735432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.